Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences


Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in fireside chats at the following investor conferences:

  • Jefferies Virtual Healthcare Conference on June 3, 2021 at 1:30 PM ET
  • JMP Securities Life Sciences Conference on June 16, 2021 at 4:00 PM ET

A live webcast of both events will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. A replay of both webcasts will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumors. For more information, visit https://www.deciphera.com/ or follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005257/en/

Deciphera Pharmaceuticals Aktie

23,80 €
-0,85 %
Leichte Verluste bei der Deciphera Pharmaceuticals Aktie heute, ein Rückgang um -0,85 %.
Einseitige Zustimmung für Deciphera Pharmaceuticals mit mehreren Buy- und keiner Sell-Einschätzung.
Mit einem Kurs von 23.8 € erreicht Deciphera Pharmaceuticals das von der Community anvisierte Kursziel von 24 €.
Like: 0
Teilen
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Rechtlicher Hinweis

Kommentare